Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Synopsis:
This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or cannot be removed surgically. Monoclonal antibodies, such as pembrolizumab and bevacizumab, may inhibit tumor cell growth and spread. Chemotherapy drugs, such as capecitabine, function in many ways to halt tumor cell growth, either by killing the cells, preventing them from growing, or preventing them from spreading. Capecitabine combined with pembrolizumab and bevacizumab may be more effective in treating colorectal cancer patients.